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ABSTRACT 
FUNCTIONALIZING NANOPARTICLES WITH CAFA PROTEIN 
TO TARGET BAR PEPTIDE FOR ORAL DELIVERY 
APPLICATIONS 
May 1, 2020 
Background: Porphyromonas gingivalis adherence to Streptococcus gordonii 
may be important for P. gingivalis colonization in the oral cavity. Nanoparticles 
encapsulating synthetic peptide BAR (BAR-NPs) inhibit P. gingivalis adherence 
more potently than free BAR. However, BAR-NPs would exhibit low retention 
in an open flow environment. 
Hypothesis: Targeting BAR-NPs to the streptococcal surface using CafA protein 
will enhance their efficacy. 
Methods: CafA-modified NPs encapsulating BAR were synthesized using double 
emulsion approach. Surface binding and retention, and release kinetics of BAR 
v 
from CafA-modified NPs was assessed. Functional inhibition assays were 
performed using dual a species biofilm. 
Results: CafA-modified NPs demonstrated specificity of adhesion, remained 
bound to S. gordonii surfaces and released inhibitory concentrations of BAR for 
over 8hr. CafA-modified NPs inhibited P. gingivalis adherence to S. gordonii 
potently for over 8hr. 
Conclusions: CafA-modified NPs represent a delivery vehicle that targets BAR 
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Periodontitis is the chronic inflammation of tooth-supporting structures, which begins as 
gingivitis and progressively leads to the destruction of periodontal ligament and alveolar bone. 
From 2009 to 2012, 46% of adults (age > 30 years) in the United States, were diagnosed with 
periodontal diseases. Of these, 8.9% had advanced periodontitis. Domestically, over 14 billion 
dollars are spent annually towards the prevention and treatment of periodontal diseases [1]. 
Periodontal disease is the major cause of tooth loss after the age of 30 and has been 
associated with systemic diseases, such as cardiovascular diseases, type 2 diabetes mellitus, 
low birth weights, premature labor and osteoporosis [2]. Periodontitis is caused by the 
interplay of host susceptibility and changes in the normal microbiota of dental plaque  [3]. 
Role of biofilm in periodontal disease 
Periodontal disease is a biofilm-mediated infection. Biofilms consist of a consortium of 
organisms that are embedded in a matrix containing extracellular polymeric substances 
(EPS). As the bacterial colonies in the biofilm grow, the biofilm develops “emergent properties” 
which differ from those of organisms in the planktonic phase [4]. These properties protect the 
biofilm and render them resilient to minor environmental alterations. However, environmental 
alterations beyond a threshold could prompt competitive overgrowth of certain 
microorganisms, leading to dysbiosis and disease [5]. Gaining a thorough understanding of 
the mechanism of biofilm formation, its  properties, and disease etiology will aid in developing 
effective therapeutics for periodontal diseases.
2 
Formation of dental plaque 
Dental plaque is a highly complex biofilm consisting of a diverse bacterial community and their 
products [6]. It forms via a series of specific, sequential molecular interactions between 
bacteria and host surfaces that ultimately result in the development of a structurally and 
functionally organized heterogenous microbial community  [7]. 
Stages of plaque formation: 
(i) Initial Adhesion  
The formation of dental plaque begins with the developpment of  acquired pellicle on the tooth 
enamel. The acquired pellicle is a thin coating formed by the adsorption of proteins and other 
macromolecules from the saliva and gingival crevicular fluid on the tooth surface. It is 
comprised of proline-rich proteins (PRPs), albumin, sialic acid, alpha amylase, and 
glycoproteins, and provides substrates for attachment to early colonizing bacteria [8]. 
Streptococci constitute 80% of these primary colonizers [9, 10] and bind to components of the 
salivary pellicle via adhesins, e.g., antigen I/II protein family, amylase-binding adhesin (AbpA), 
and serine-rich repeat glycoproteins (Has, GspB) [8, 11, 12]. Actinomyces oris is another 
primary colonizer and its adherence to the PRPs and statherin of the salivary pellicle is 
mediated via type 1 fimbriae [13]. Initial adherence of the bacteria to the tooth surface is a 
crucial event in plaque development which prevents the organisms from being washed away 
by mechanical shearing forces of salivary fluid flow and tongue movement [14]. 
(ii) Bacterial Coaggregation and Biofilm Maturation  
After initial adherence, the plaque evolves to contain additional species of bacteria, primarily 
consisting of gram-negative rods. Biofilm formation and growth occurs by the adherence of 
secondary colonizers to already attached bacterial cells and their metabolic products [14, 15]. 
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Specific interspecies bacterial adhesion is termed coaggregation and leads to an increase in 
the biovolume and complexity of the biofilm [16]. Coaggregation can occur via direct cell-cell 
interactions mediated by reciprocal adhesin-receptor binding or via multivalent molecules 
such as mucin and glucans [14]. Bacterial coaggregation promotes microbial interactions by 
co-locating physiologically relevant organisms in the same milieu, thereby facilitating 
development of complex nutritional co-operation, gene transfer and cell-cell signalling [5]. In 
microbial communities, nutritional interdependence develops amongst the residing 
organisms, where the product of metabolism of one bacterial species becomes the food 
source for another, resulting in the development of food webs [4]. Furthermore, metabolic 
pathways drive the order of colonization, whereby different layers of the biofilm are associated 
with a specific metabolic pathway that results in a functionally-structured community [17]. The 
close proximity of the cells also facilitates horizontal gene transfer and increases the adaptive 
ability of the organisms to changing oral environment [18]. Moreover, cell-cell signalling 
enables bacterial cells to sense and adapt to various environmental stimuli and control the 
expression of virulence-regulating genes [5]. 
As the biofilm grows by bacterial coaagregation, the organisms induce the genetic program 
to promote biofilm formation which facilitates interbacterial agglutination by the formation of a 
slimy matrix. All microorganisms residing within biofilms are embedded in this matrix 
containing extracellular polymeric substances (EPS) [19]. The matrix allows the bacteria to 
adhere to each other and the colonizing surfaces, protects the bacteria from host defenses, 
enhances the mechanical stability of the biofilm, facilitates communication between bacterial 
species, and forms chemical/nutrient gradients that create microenvironments within the 
biofilm which vary widely in pH, oxygen and nutrient availability [20, 21]. Thus the matrix allows 
individual bacterial cells to behave as a cohesive multicellular unit, whose properties and 
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characteristics collectively differ from those of free-living bacteria. These “emergent 
properties” of the biofilms make them more conducive to survival in harsher environments [4, 
21]. 
(iii) Biofilm Dispersion  
Detachment of cells from the mature biofilm occurs by various processes, e.g., mechanical 
sloughing, enzymatic degradation of biofilm matrix, and downregulation of genes responsible 
for matrix production [15, 22]. The detached cells disperse and can initiate the formation of a 
new biofilm under favorable conditions [22] .  
These details surrounding the process of biofilm formation can  provide insights for developing 
novel, effective strategies to prevent their initial formation (prophylactic approach) and disrupt 
existing biofilms (therapeutic approach). Treating biofilm-mediated infections poses a special 
challenge due to the “emergent properties” of the biofilm and the resulting biofilm-mediated 
resistance [22, 23]. The effectiveness of antibiotics in treating biofilm-mediated infections is 
limited due to: (i) compromised penetration of antibiotics through the polysaccharide matrix of 
the biofilm [24], (ii) increased drug resistance of bacteria in the biofilm versus planktonic state 
[23], and (iii) reduced/altered cellular activity of bacteria within the biofilm [25]. Some novel 





Figure 1: (A) Schematic representation of plaque development.  (B) Schematic representation 
of anti-biofilm strategies (i) coating tooth surfaces with materials to limit initial bacterial 
adherence and prevent biofilm formation, (ii) interrupting bacterial communication to inhibit 
development of biofilm properties such as expression of virulence factors, And (iii) disrupting 
pre-established mature biofilms using “anti-biofilm” peptides and matrix degrading enzymes 
leading  to biofilm destabilization. 




Etiology of periodontal diseases 
The oral cavity harbors more than 700 bacterial species, some of which have been implicated 
in the initiation and progression of periodontal diseases. In a study done by Socransky et al., 
it was observed that periodontal diseases are caused by a consortium of organisms rather 
than individual pathogens. Moreover, the composition of the microbiome at healthy and 
diseased periodontal sites varied drastically and certain microbes were repeatedly found 
clustered together at diseased and healthy sites. Based on these findings, five microbial 
complexes were defined. Of these, the red complex, which appears later in biofilm 
development, and comprises three species, Tannerella forsythia, P. 
gingivalis and Treponema denticola, has been considered to be the most pathogenic 
microbial complex [26-28].  
 
In recent times, metatranscriptome analysis of dental biofilms from sites with active 
periodontal disease have found that in addition to periodontal pathogens such as Tannerella 
forsythia and P. gingivalis, organisms such as Veillonella parvula, Pseudomonas fluorescens 
and various streptococci are highly active in transcribing putative virulence factors [29]. These 
findings have provided evidence for the role of the entire community and not just a few 
pathogens in causing the disease.  
 
Our current understanding of periodontal disease is based on the Polymicrobial Synergy and 
Dysbiosis model, which proposes that periodontitis is caused by the dysbiosis of the host 
microbiome, rather than an exogenous pathogen [3]. P. gingivalis has been shown to play a 
key role in inducing dysbiosis by modulating the innate host responses and elevating the 
virulence of the microbiome by altering gene expression via interspecies signalling [3, 30]. 
 
7 
One of the proposed ways in which P. gingivalis modulates host immunity is by initiating 
C5aR1-TLR2 crosstalk to subvert immune response and promote inflammation [31, 32]. 
P. gingivalis also suppresses the expression of IL-8 and Th1 chemokines which aid in the 
recruitment of neutrophils. Transient delays in neutrophil recruitment facilitate initial 
colonization and allow an increase in the overall microbial load [33]. Uncontrolled bacterial 
growth disrupts tissue homeostasis and triggers a robust inflammatory response causing 
tissue breakdown [34]. Under these circumstances, bacterial species that thrive well in an 
inflammatory environment may outcompete those that do not, resulting in a shift in the host 
microbiome towards a disease-causing microbiota [3]. Subsequent tissue breakdown yields 
nutrients (e.g., degraded collagen and heme compounds) which promote the growth of 
subgingival proteolytic and asaccharolytic bacteria. The gene expression of the microbial 
community is altered such that genes associated with proteolysis and LPS synthesis are 
upregulated [35-37], which in turn leads to more inflammation. The dysbiosis-inflammation 
interplay generates a vicious cycle that drives periodontitis [35, 38, 39].   
In summary, P. gingivalis may exert a community-wide effect in oral biofilms. It modulates the 
host immune response to facilitate an overall increase in bacterial load, along with a shift in 
microbial composition to a more disruptive microbial community. The altered microbiota 
triggers an uncontrolled inflammatory host response leading to periodontal tissue destruction. 
P. gingivalis also alters the gene expression of the microbiome [40]. Thus, P. gingivalis plays 
a key role in promoting dysbiosis and elevating the virulence of the host microbiome.  
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Treatment of periodontal diseases 
The conventional treatment of periodontal diseases involves the mechanical removal of 
plaque/calculus by scaling and root planning, along with the use of antibiotics, administered 
by systemic or local routes, as adjuncts to prevent its reoccurrence [41-44]. Systemically 
delivered antibiotics reach the deep periodontal pockets, which are not amenable to 
professional cleaning, via serum, but require patient compliance and must be administered at 
a higher dose to be effective [45]. However, chronic, indiscriminate use of antibiotics in the 
treatment of periodontal disease may lead to adverse side effects such as toxicity, allergies, 
alteration of gut microflora and increased antimicrobial resistance [46]. Moreover, antibiotic 
effectiveness in periodontal treatment is limited due to biofilm-mediated resistance and the 
prevalence of resistant pathogens. In a recent study, 25.49%, 23.52% and 21.56% of 
P. gingivalis isolates from patients with periodontitis were found to be resistant to amoxicillin, 
clindamycin and metronidazole, respectively [47].  
Organisms such as P. gingivalis can also evade host immune surveillance by residing and 
multiplying within gingival epithelial cells and preventing host cell apoptosis posing a special 
challenge in the treatment of periodontitis [48, 49]. At disease sites, P. gingivalis have been 
found to reside within all the layers of the epithelial tissue and in the connective tissue [50]. 
Commonly used antibiotics such as metronidazole do not readily cross the plasma membrane 
of cells and therefore are inefficient at killing intracellular organisms. In many cases, after the 
cessation of antibiotic therapy, these intracellular organisms recolonize periodontal tissue and 
cause recalcitrant disease. These findings underscore the importance of developing 
innovative, antimicrobial agents for targeting oral pathogens.  
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Why target P. gingivalis? 
A  longitudinal metatranscriptomic analysis of microbiota from stable to disease-progressing 
sites showed that only P. gingivalis expressed virulence factors at healthy sites, whereas the 
virulence of T. denticola and T. forsythia was upregulated after tissue breakdown [29]. This 
suggests that of all the red complex organisms, P. gingivalis likely initiates dysbiosis at healthy 
sites and other organisms contribute to the acceleration of disease process after homeostasis 
has already been disrupted [30]. Thus, although P. gingivalis is not essential for periodontal 
diseases, it is an important risk factor in periodontal diseases [30].  
Studies have also shown that antibody levels to P. gingivalis are consistently higher in patients 
diagnosed with adult periodontitis [51, 52]. These findings, combined with the role of P. 
gingivalis in inducing host dysbiosis and modulating immunity, makes targeting P. gingivalis 
an effective strategy for developing novel therapies for the prevention and treatment of 
periodontal diseases. 
Current novel treatment strategies targeting P. gingivalis 
• Quorum sensing inhibitors (QSI)
Bacteria in biofilms produce signalling molecules called autoinducers (AI) to communicate
with each other. As the density of the bacteria increases, the concentration of AI also
increases. By sensing the concentration of AI in the environment, bacteria gauge their
population density, and when the density of the population reaches a certain threshold, it
triggers gene expression.. This mechanism of intercellular signalling is known as quorum
sensing (QS) (Figure 2).
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Differential gene expression in response to quorum sensing allows bacteria to modulate their 
phenotypes and behavioral activities when growing in biofilms.  At low densities, the bacteria 
behave as solitary organisms; however, at high densities they develop beneficial traits that 
facilitate their survival at a community-level. Quorum sensing-dependent activities include 
biofilm development, expression of virulence factors and bioluminescence [53]. For P. 
gingivalis specifically, the LuxS/AI-2 signalling system is used for quorum sensing and biofilm 
development [54, 55]. Therefore, inhibiting this signalling system can potentially weaken 
biofim formation and suppress the expression of the quorum controlled virulence genes [56]. 
QSI such as furanone compound [(5Z)-4-bromo-5-(bromomethylene)-2(5H)-furanone] and D-
ribose inhibit AI-2 and have been shown to inhibit P. gingivalis biofilm formation in vitro and 





                             
           Figure 2: Schematic represention of the mechanism of quorum sensing in bacteria. 
           Image adapted from: Parray, J., et al., Quorum Sensing: Melody Beneath the Ground. 2018. p. 
118. Sankar Ganesh, P. and V. Ravishankar Rai, Alternative Strategies to Regulate Quorum 
Sensing and Biofilm Formation of Pathogenic Pseudomonas by Quorum Sensing Inhibitors of 




• Naturally Derived Compounds
Plant and marine based compounds such as essential oils, capsaicin, chitosan (crustaceans),
andOligoG (oligosaccharide from brown algae alginate) that have the potential to inhibit P.
gingivalis biofilm formation are currently being investigated for therapeutic use [58]. Presently,
a thorough understanding of their precise mechanism of action and cytotoxic potential is
lacking, which precludes their use as therapeutic agents [58]. However, some are believed to
induce this effect by reducing P. gingivalis adherence to gingival epithelial cells, interfering
with proteolylic activity of gingipain and inhibiting cytokine secretion. Some naturally derived
compounds and their mechanism of action have been listed in Table 1 [59-61].




Mechanism of Action 
 A-type 
cranberry     
proanthocyanidin 
• Anti- P. gingivalis biofilm activity
• Anti-inflammatory (Inhibits IL8 & chemokine ligand 5 secretion)
• Reduces the adherence of P. gingivalis to oral epithelial cells
Lacinartin 
• Anti- P. gingivalis biofilm activity
• Reduces the adherence of P. gingivalis to oral epithelial cells
• Disrupts pre-formed biofilms
Prenylated 
flavonoids 
• Inhibits P. gingivalis biofilm
• Interferes with Rgp and Kgp gingipain activity
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• Antimicrobial Peptides (AMPs)
Antimicrobial peptides have been deemed as promising drug candidates since they are
conserved and therefore exhibit broad-spectrum activity. AMPs target negatively-charged
bacterial cell membranes and kill bacteria by membrane disruption or pore formation [62].
Synthetic AMPs can be engineered to be species-specific with the addition of a targeting
moiety [63, 64]. AMPs also have a lower tendency to induce resistance compared to
conventional antibiotics [64]. Some currently studied antimicrobial peptides are discussed
below.
§ Lactoferrin (LF) is an iron binding glycoprotein and plays an important role in innate immunity.
The lipopolysaccharide (LPS) found on the outer membrane of P. gingivalis is a crucial
virulence factor that mediates its biofilm formation. Lactoferrin binds to LPS and inhibits biofilm
formation. Additionally, P. gingivalis has an absolute requirement of iron for its growth and LF,
due to its ability to sequester iron, can inhibit its growth [65].
§ Nal- p-113 is a cationic AMP which exhibits bactericidal activity by perforating the
plasmalemma, resulting in cell death. Moreover, it is resistant to proteolytic degradation. In
vitro studies have shown that it is effective in eradicating P. gingivalis in the planktonic state
and inhibiting subsequent biofilm formation [66].
§ BAR peptide is a synthetic peptide derived from a  specific region of the streptococcal SspB
polypeptide (residues 1167 to 1193) and is comprised of the functional motifs VXXLL and
NITVK. BAR peptide blocks the interaction between P. gingivalis and S. gordonii and
therefore limits the colonization of P. gingivalis and has been shown to reduce virulence in
murine model of periodontitis [67].
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• Small molecules:
Owing to the high cost of peptide synthesis and the susceptibility of peptides to degradation
by proteases [68], small molecules with antimicrobial activity against P. gingivalis are being
researched for therapeutic potential. For example, BAR peptide consists of lysine residues
that are susceptible to Lys-gingipain expressed by P. gingivalis. 1,2,3-Triazole-based
compounds, formed by joining the synthetic mimics of the functional motifs of BAR peptide
(VXXLL and NITVK) by a click-reaction, have been found to be compact, stable and potent
inhibitors of P. gingivalis – S. gordonii biofilm formation [69, 70]. Of these compounds, PCP-
III-201 was found to inhibit P. gingivalis biofilm formation even in the presence of
F. nucleatum, to disrupt pre-established three-species biofilms, and to significantly reduce
alveolar bone loss in murine models of periodontitis [71].
Use of nanotechnology in the control of biofilm mediated infection 
In recent times, nanoparticles (NPs) have emerged as promising delivery vehicles to combat 
biofilm formation due to their unique nanoscale physicochemical properties [72]. Properties 
such as NP size, shape and surface charge help to facilitate or hinder penetration into biofilms 
via fluid channels. The self-diffusion coefficient of NPs decreases with the square of the NP 
radius [73]. For a constant volume, decreasing the size and increasing the aspect ratio 
enhances the efficacy of the NP [74]. Furthermore, while anionic and neutral quantum dots 
have been shown to have difficulty penetrating biofilms, cationic quantum dots have been 
found to widely distribute throughout biofilms. In addition, factors such as hydrophobicity can 
impact bacterial internalization or localization at the bacterial surface. As one example, 
cationic quantum dots with hydrophobic terminal groups are more readily internalized by the 
bacteria relative to hydrophilic quantum dots which remain in the EPS matrix of the biofilm 
[75]. Hence, manipulation of physical attributes such as size and shape, combined with 
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chemical characteristics of surface charge and hydrophobicity, can enhance NP penetration 
and alter their ability to be internalized by bacteria.  
Along with improved biofilm penetration and increased cellular uptake, another advantage of 
NPs is the reduced likelihood of resistance development since NPs use several mechanisms 
simultaneously to combat microbes [76]. For instance, chitosan nanoparticles have a positive 
charge and therefore can associate with negatively-charged bacterial cell walls, increase cell 
permeability and cause osmotic damage. Additionally, chitosan can bind to DNA in bacterial 
cells and inhibit mRNA transcription and protein translation. It may also decrease the activity 
of metalloproteins by chelating metals [77]. Therefore, multiple simultaneous genetic 
mutationions are required to occur in the same bacterial cell for resistance development. NPs 
may also be used to overcome existing bacterial resistance mechanisms such as permeability 
regulation, multidrug efflux pumps and target site mutations [78-80]. Figure 3 depicts some 
advantages of using nanosized carriers as drug delivery systems over traditional systematic 
and local routes. A more in-depth description of delivery vehicle options that can be used in 










Figure 3: Overview of drug delivery systems.  
Image adapted from: Zupancic, S., et al., Contribution of Nanotechnology to Improved 
Treatment of Periodontal Disease. Curr Pharm Des, 2015. 21(22): p. 3257-71. 
 
 
• Systemic administration, e.g., tablets and capsules
• Advantages: Ease of administration, inexpensive.
• Disadvantages: High therapeutic dose, low concentration at target 
sites, distritution throughout the body, side-effects, resistance 
development, frequent dosing. 
• Local drug delivery systems, e.g., films and fibers
•Advantages: High concentration at target sites, less frequent dosing, 
lower dosing requirements, fewer side-effects, bypass first-pass 
effects.
•Disadvantages: Limited dose due to smaller area, need for removal 
(fibers), burst release (gels). 
• Nanocarrier drug delivery systems, e.g., nanoparticles 
and nanofibers
•Advantages: Improved drug stability, protection of drug/peptides, 
improved retention and bioadhesiveness, targeted delivery, high 
intracellular uptake. 
•Disadvantages: Unknown safety profile, complex preparation. 
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A wide variety of materials have been used to fabricate nanoparticle delivery vehicles for oral 
applications, which include metals and metal oxides, such as silver [81]; gold and copper [82, 
83]; lipids [84]; and polymers [85]. Metal and metal oxide particles have been used due to 
their inherent antimicrobial properties [86]; however, there are several concerns regarding the 
toxicity associated with their accumulation at target sites [87]. Biodegradable materials such 
are polymers have gained popularity in recent times due to their biocompatibility, reduced 
side-effects, diverse features (e.g., hydrophilicity, lipophilicity) and ease of modifying their 
physical properties by changing their chemical structure or by using polymer blends to 
optimize NP function [88, 89]. Owing to their ability to be internalized, polymeric NPs can be 
developed to address special challenges posed by intracellular dwelling organisms such as 
P. gingivalis that can cause recalcitrant disease. Polymersomes encapsulating metronidazole 
have been shown to penetrate through two-third of the epithelium in 24 hr and reduce 
intracellular P. gingivalis levels significantly relative to free drug, due to their ability to be 
internalized by the gingival epithelial cells [90]. Polymeric nanoparticle that repond to stimuli 
have been developed to provide more control over the release of the active agent and diminish 
undesirable side effects. These NPs demonstrate therapeutic selectivity by responding to 
stimuli such as shifts in pH, pressure, temperature and oxygen [91].  Horev et al. designed 
farnesol loaded pH-responsive polymeric nanoparticles to bind avidly to the pellicle and EPS 
of the biofilm, enhancing drug retention at target sites at physiologic pH. The nanoparticles 
were tuned to rapidly release the drug when the local pH became acidic, as would be observed 
in a cariogenic environment [92]. 
In addition to the aforementioned features, polymeric nanoparticles offer some special 
advantages such as the protection and stabilization of drugs/proteins, high drug loading 
capacity, controlled and sustained drug release, modifiable rate of polymer degradation and 
drug release. The rate of polmer degradation can be reduced with the use of hydrophobic 
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polymers such as polylactic acid (PLA) and polycaprolactone (PCL) which decrease the 
diffusion of water, whereas, the use of hydrophilic polymer such as polyglycolic acid (PGA) 
demonstrates the opposite effect. Additionally, the size and surface characteristics of 
polymeric NPs can also be easily manipulated to promote penetration of NPs, increase 
residence time at target sites and enable site-specific targeting [93]. Lately, there has been a 
tremendous interest in developing targeted NPs to improve safety, biodistribution and efficacy 
of drugs. In vivo, targeting has been shown to increase accumulation and retention of NPs at  
target sites free drug  [94-97]. Moreover, localized release of encapsulated agent from the 
accumulated NPs at the target sites can enhance the potency of the drug relative to free drug  
[94-97]. 
 
Development of targeted nanoparticles  
Two basic strategies of active and passive targeting have been applied to design NPs that 
promote site-specific delivery of active agents. Passive targeting relies on the 
physicochemical properties of the NPs (i.e., size, surface charge, mucoadhesivity) and 
features of the disease causing agent/disease process (negative charge on bacterial surfaces, 
leakiness of tumor vasculature) [98]. Passive targeting strategies have involved integrating 
carboxymethyl cellulose (CMC) [99], polyacrylic acid (Carbopol) [100], polyethylene glycol 
(PEG) [101, 102], polyvinyl alcohol (PVA) [103] or polyvinyl pyrrolidone (PVP) [103, 104] on 
the surfaces of NPs, which has been shown to improve NP retention and accumulation at 
target sites. The nanoparticles act as drug depots at target sites and release the active agent 
at the desired sites in a controlled and sustained manner [105]. Chitosan has been widely 
used in oral applications, due to its inherent mucoadhesive properties [106].  
 
In comparison, active targeting relies on a biological interaction between ligands on the NP 
surface and target cell receptors. The use of specific targeting ligands has been shown to 
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increase NPs binding efficiency by more than two to four-fold at target sites, due to multivalent 
interactions [107-109]. Moreover, minimizing non-specific interactions between NPs and non-
target cells helps to reduce indiscriminate distribution of active agents at non-target sites and 
promotes localized delivery to target sites, enhancing NP efficacy [110, 111].  
Polymeric nanoparticles and treatment of periodontal diseases 
Both passively and actively targeted NPs have been developed for use in the treatment of 
periodontal disease.  
Passively targeted NPs 
Chitosan NPs have been extensively used as passively targeted NPs due to their 
mucoadhesive properties. NPs formulated using thiolated chitosan (TCS)-poly (methacrylic 
acid) (PMAA) (TCS-PMAA) encapsulating metronidazole benzoate (MET) have been shown 
to exhibit high mucoadhesiveness due to water uptake from the mucosal tissue by adsorption, 
swelling and capillary effect, leading to stronger adhesion. These NPs also demonstrated 
sustained release of MET over 24 hr and improved its oral availability at target sites [112]. In 
another study, PLGA-lovastatin-chitosan-tetracycline nanoparticles were found to exhibit 
potent antibacterial activity against A. actinomycetemcomitans and P. nigrescens in vitro. 
They also improved alkaline phosphatase activity leading to a significant increase in new bone 
formation in beagle dogs [113].   
Actively targeted NPs 
Actively targeted NPs involve modifying the surfaces of the NPs with biological ligands that 
promote specific interactions between the ligands on the NP surfaces and target cell 
receptors. Several biological ligands such as antibodies, aptamers, peptides and small 
molecules have been used to modify the surfaces of the NPs to improve their binding 
efficiency on target cells [94, 95]. Often, ligands are directed to exploit endogenous differences 
between normal and pathological tissues and to direct therapy to classical or diseased target 
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site markers. As one example in periodontitis, inflamed gingival epithelial cells express a 
higher level of the b1 integrin including a2b1, a3b1, a5b1 and a6b1, relative to normal epithelial 
cells. Surface modification of NPs with a peptide, RGD, which binds to the b1 integrin, helps 
to facilitate NP adherence and retention at periodontal disease sites for a prolonged duration. 
As such, minocycline-loaded poly(ethylene glycol)-poly(lactic acid) (PEG–PLA) NPs 
functionalized with RGD peptides demonstrated potent anti-periodontitis activity relative to 
non-targeted NPs and free minocycline [114]. Additionally, RGD-modified minocycline NPs 
delivered a higher localized concentration of minocycline to the gingiva and retained the 
effective concentration for a longer duration, relative to unmodified minocycline  NPs [114].   
While few studies have employed active targeting approaches for the treatment of periodontal 
diseases, previous work in our group sought to utilize the targeting capabilities of BAR peptide 
to improve NP targeting, and thereby enhance potency, via surface-modification. In our 
previous work, we developed PLGA nanoparticles functionalized with a synthetic peptide 
(BAR) (IC50=0.2 µM), and showed that BAR-modified NPs are more efficacious and inhibit 
P.gingivalis adherence to S. gordonii more potently relative to free BAR (IC50=1.3 µM)  in vitro. 
In murine models of periodontitis, BAR-modified NPs reduced alveolar bone loss and 
promoted an anti-inflammatory response by decreasing the expression of IL-17, a pro-
inflammatory cytokine [115].  
Considerations for developing actively targeted nanoparticles 
Although active targeting can enhance NP efficacy by improving binding efficiency to target 
cell receptors, increasing NP residence time at target sites and promoting the localized 
delivery of active agents, several factors must be considered in the design of optimally 
functioning actively-targeted nanocarriers. Generally, increasing the surface ligand density 
improves the receptor binding avidity of surface-modified NPs by promoting multivalent 
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interactions. However, several studies have found that NPs with an intermediate ligand 
density are more efficacious and exhibit higher binding relative to higher ligand density NPs  
[116-118]. This may be due to steric hindrance that affects receptor accessibility (Figure 4A); 
increased size of NPs following surface modification, which limits NP diffusion to receptors at 
target sites; and improper ligand orientation, with high packing density that interferes with 
ligand functionality [105, 119]. It has also been found that the addition of surface ligands 
improves binding efficiency only if the receptors are spaced closely enough together to allow 
for multiple ligands on the same NP to simultaneously bind to several target cell receptors 
(Figure 4B) [119]. Furthermore, receptor clustering due to multiple receptor binding on the 
target cell could result in cell activation, proliferation and other adverse effects [105]. 
Moreover, surface modification with target ligands may impede the release of the encapsulant. 
Slower release rates may result in lower available concentrations of the active agent at the 
target sites and reduced effectiveness of the surface-modified NPs [107]. Therefore, while 
designing NPs for optimal function, the addition of ligands to enhance binding efficiency must 
be weighed against its impact on key parameters including encapsulation efficiency, release 











Figure 4: Considerations for developing actively targeted nanoparticles. (A) High ligand 
density may not always improve NP binding efficiency. One reason may be limited 
accessibility to receptors on the target cell. (B) Binding efficiency improves only when multiple 
ligands on the same NP bind to multiple receptors on target cell, promoting multivalent 
interactions. However, when receptors on target cell are placed further apart and do not allow 
for multiple ligands on the same NP to bind to them simultaneously, addition of ligands does 








Oral biofilm formation occurs via sequential, species-specific bacterial coaggregation. 
One of the bacteria involved in this coaggregation is P. gingivalis, a gram-negative, 
assacharolytic, obligatory anaerobe that resides mainly in the subgingival sulcus [120]. 
However, the subgingival colonization of P. gingivalis is likely to occur only after its initial 
colonization within the supragingival biofilm. The initial supragingival colonization of P. 
gingivalis is mediated through interactions with certain species of oral streptococci and/or 
Fusobacterium nucleatum that provide physiologic support to facilitate its survival in the 
supragingival environment [121]. After its supragingival colonization, P. gingivalis disperse 
and colonize in their preferred niches of the anaerobic subgingival sulcus [120]. Given the 
downstream events initiated by P. gingivalis binding, these initial supragingival interspecies 
interactions present viable targets for early therapeutic intervention to limit P. gingivalis 
colonization.  
One of the primary organisms that promotes the supragingival colonization of P. gingivalis is 
S. gordonii. Adherence of P. gingivalis to S. gordonii is a multimodal protein-protein interaction 
that involves both the short and long fimbriae of P. gingivalis [122]. FimA, the structural subunit 
of the major fimbriae, interacts with cell surface glyceraldehyde 3-phosphate dehydrogenase 
of S. gordonii [123, 124], while Mfa1, the structural subunit of the minor fimbriae, interacts with 
discrete domains of the streptococcal cell surface protein SspB of the antigen I/II family [125]. 
The Mfa-SspB interaction is the driving force that mediates interbacterial coaggregation and 
is essential for the development of P. gingivalis biofilms on a streptococcal substratum. SspB 
polypeptide is 1500 residues in length and consists of seven structural domains that are 
conserved in all antigen I/II polypeptides. A region encompassing residues 1167 to 1250 
promotes the adherence of SspB protein of S. gordonii to P. gingivalis [126]. Although virtually 
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all oral streptococci express antigen I/II proteins, P. gingivalis selectively adheres to certain 
species such as S. oralis and S. gordonii but not S. mutans and S. intermedius. Further 
comparison of the adherence-promoting region of SspB protein of S. gordonii to the 
corresponding region of S. mutans antigen I/II showed that a protein determinant comprising 
of 1167 to 1193 was adequate to promote P. gingivalis adherence [127]. The recognition of 
this discrete structural motif of SspB (SspB Adherence Region), that is not conserved in SspA, 
a related antigen I/II protein of S. mutans, accounts for the species specificity of P. gingivalis 
adherence. More specifically, Asn 1182, Thr 1184 and Val1185  in SspB are not conserved in the 
SpaP sequence of S. mutans [127]. 
The synthetic analog of SspB adherence region (BAR), comprised of residues 1167 to 1193, 
also potently inhibits Mfa-SspB interaction. It consists of two structural motifs, VXXLL and 
NITVK (amino acids 1171 to 1180 and 1182 to 1186, respectively in the full-length antigen I/II 
protein of S. gordonii) which are essential for the interaction of the peptide with Mfa. 
Additonally, a motif EXXP, upstream of VXXLL, also contributes to the interaction. Analogs of 
BAR that lack the EXXP motif, exhibit a lower specific activity relative to BAR [67, 128]. In a 
study by Daep et al. it was found that P. gingivalis bound efficiently to BAR-like peptides with 
amino acid substitutions at both the non-conserved residues 1182 and 1185.  Substitution of 
positively-charged amino acids at position 1182 and hydrophobic residues at 1185, further 
enhanced the activity of the peptide, whereas substitution with acidic residues at position 1182 
reduced P. gingivalis adherence and no other amino acids were tolerated at position 1185. 
These findings suggest that the (i) properties and characteristics of the amino acids occupying 
these positions were more important, not the specific amino acids, and (ii) Mfa-SspB 
interaction is driven by both electrostatic and hydrophobic bonding [67]. Substitution of 
cysteine residues for Leu1167 and Leu1191, which yielded a cyclic structurally-constrained 
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peptide was found to be a more competitive inhibitor of P. gingivalis biofilm formation than 
BAR peptide, suggesting that the secondary structure and conformation of the peptide is 
crucial to the function of the peptide. Overall these results suggested that peptides or 
peptidomimetics with greater specific inhibitory activity than that of BAR can be synthesized. 
In vivo studies demonstrated that BAR peptide inhibits P. gingivalis – S. gordonii biofilm 






Figure 5: Schematic representation of P. gingivalis – S. gordonii interaction. P. gingivalis – S. 
gordonii adhesion is mediated via the interaction of major (fimA) and minor fimbriae (Mfa1) of 
P. gingivalis and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and discrete 
domains on SspA/B (Antigen I/II) adhesin of S. gordonii, respectively. The domains of SspA/B 
that interact with the minor fimbriae subunit, Mfa1, are highlighted on the right. These domains 
reside within the SspA/B adherence region (BAR) and are required to promote P. gingivalis 
adherence. P. gingivalis does not adhere to organisms lacking the BAR motif in the antigen 
I/II protein.  
Image: Wright, C.J., et al., Microbial interactions in building of communities. Mol Oral 






P. gingivalis – S. gordonii Interaction (Figure 6A and B) 
P. gingivalis – S. gordonii aggregation is mutualistic and tightly regulated. P. gingivalis – S. 
gordonii aggregration is regulated by contact-based signalling and through the detection of 
diffusible mediators such as para-amino benzoic acid (pABA). These interactions initially 
facilitate the formation of heterotypic community and ultimately limit the development of 
excessive microcolonies to prevent states of depleted nutrition and exposure to elevated 
levels of oxygen [130, 131].  
The accumulation of P. gingivalis on a substratum of S. gordonii is facilitated by increased 
expression of mfa1 and luxS genes. Increased transcription of mfa1 results in increased 
expression of fimbrial protein, which in turn primes the organism for colonization, whereas, 
increased luxS transcription results in elevated levels of AI-2, a quorum signalling molecule 
that aids in P. gingivalis – S. gordonii community development [125, 132].   
In P. gingivalis, the expression of mfa1 is suppressed through a pathway involving Ltp1 (Low 
Molecular Weight Tyrosine Phosphatase), which dephosphorylates Ptk1 and indirectly 
upregulates the transcription of CdhR (Community Development and Hemin Regulator), a 
negative regulator of luxS and Mfa gene [130].  
Following contact with S. gordonii, a streptococci derived contact based signal propogating 
through Mfa elevates the levels of Ltp1 in P. gingivalis. Increased Ltp1 levels, indirectly results 
in increased CdhR levels, which in turn reduces the  transcription of luxS and mfa gene and 
consequently restrains P. gingivalis accumulation on S. gordonii. Furthermore, AI-2 is a 
negative regulator of CdhR. Therefore, reduced levels of luxS/AI-2 further increases cdhR 
expression which further constrains community development. Thus, reduction of AI-2 levels 
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compensates for the loss of contact based signalling due to the reduction of Mfa fimbrial 
expression and continues to restrain community development [130].  
CdhR is a positive regulator of hmu operon involved in hemin uptake and dephosphorylation 
of gingipain proteases. Increased levels of CdhR increases hmu transcription and in turn 
elevates the pathogenic potential of the organism [130].  
In summary, the activation of Ltp1-CdhR pathway in P. gingivalis via contact-based signalling 
limits P. gingivalis – S. gordonii heterotypic community development by downregulating the 
expression of mfa1 and luxS genes and increases the pathogenicity of P. gingivalis by 
upregulating the expression of hmu gene .  
Chorismate-binding enzyme encoded by cbe gene in S. gordonii produces a metabolite 4-
amino benzoate/para-amino benzoic acid (pABA) which can be released extracellularly 
(Figure 6a). PABA inactivates Ltp1-CdhR pathway in P. gingivalis and upregulates the 
expression of Mfa1 fimbrial protein. Consequently, the dephosphorylation and inactivation of 
Ptk1 is reduced.  Since Ptk1 activity converges on fimA gene, the level of FimA fimbrial protein 
is elevated. Therefore, pABA upregulates the expression of both Mfa1 and FimA, priming the 
organism for coadhesion with S. gordonii and community development. Concomitantly, pABA 
dimishes the pathogenicity of P. gingivalis by reducing the production of extracellular 
polysaccharides. However, following the aggregation of  P. gingivalis on S. gordonii, the 
calming effects of pABA are reduced, most likely due to spatial constraints in the accessibility 
of pABA and subsequently, the pathogenicity of the P. gingivalis – S. gordonii community is 
increased due to the activation of the Ltp1-CdhR pathway via contact based signalling [131].  
P. gingivalis – S. gordonii coadhesion and signalling is crucial for development of a dysbiotic 
microbial community. P. gingivalis virulence is increased following coadhesion with 
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S. gordonii . Co-infection with both bacterial species causes a greater amount of alveolar bone 
loss relative to infection with either species alone [129]. Therefore blocking these early 
interactions could potentially limit the colonization of P. gingivalis and reduce the pathogenicity 
of the subsequent biofilm.  
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Figure 6a: Schematic representation of P. gingivalis – S. gordonii signalling mechanism.  
(a) Binding of Mfa1-SspB (contact dependent signalling) increases the levels of Ltp1 and 
cdhR(indirectly). Higher levels of cdhR decreases the levels of Mfa and luxS which results in 
decreased P. gingivalis – S. gordonii aggregation. Reduction in the levels of AI-2 further 
increases the levels of cdhR and limits community development.  
Image adapted from : Chawla, A., et al., Community signalling between Streptococcus gordonii 
and Porphyromonas gingivalis is controlled by the transcriptional regulator CdhR. Mol 







Figure 6b: Schematic representation of P. gingivalis – S. gordonii signalling mechanism.  
(b) Binding of Mfa1 –SspB increases Ltp1 activity and reduces the expression of fimbrial 
adhesins. Mfa1-SspB binding also decreases the expression of chorismate binding enzyme 
(Cbe), resulting in reduced pABA production. Increased Ltp1 activity and reduced Cbe 
expression limits bacterial aggregation and enhances the pathogenicity of P. gingivalis. 
Image from: Lamont, R.J., H. Koo, and G. Hajishengallis, The oral microbiota: dynamic 








In our previous work, we demonstrated that a synthetic peptide, consisting of residues 1167 
to 1193 of the surface protein SspB expressed by S. gordonii, designated BAR (SspB 
Adherence Region), blocks the Mfa1-SspB interaction and reduces the virulence of 
P. gingivalis in murine models of periodontitis [67, 129]. However, free peptide is only retained 
transiently in the oral cavity owing to the constant flow of saliva. Moreover, while BAR potently 
inhibited the initial adherence of P. gingivalis to S. gordonii, it was less effective at inhibiting 
pre-established P. gingivalis biofilms. 
To enhance the efficacy of BAR peptide (IC50=1.3 µM),  we developed polymeric poly (lactic-
co-glycolic acid) (PLGA) nanoparticles (NPs) encapsulating BAR (BAR-NPs). These NPs 
inhibited P. gingivalis – S. gordonii biofilm formation more potently relative to free peptide (IC50
= 0.7 µM). BAR-NPs also disrupted pre-established biofilms more potently than free BAR. 
 We envision our NPs to be ultimately incorporated in oral hygiene products such as oral gels 
which are used two to three times daily. Hence, we ideally seek to develop NPs that will be 
retained in  the oral cavity and release inhibitory concentrations of BAR peptide for a minimum 
of 8 to 12 hours. However, BAR-NPs released  > 50% of BAR peptide within the first 2 hr of 
delivery and would exhibit low retention in an open flow environment such as the oral cavity 
[133]. Hence, the BAR-NPs would benefit from a strategy that would improve their retention 
in the oral cavity and promote a gradual release of the BAR peptide.  
Several approaches have been employed to improve NP retention, including alteration of 
properties such as surface charge and hydrophobicity, and functionalizing NPs with non-
specific mucoadhesive or specific targeting ligands that bind to host receptors [134]. As 
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previously discussed, the use of specific targeting ligands has been shown to increase NP 
binding efficiency at target sites, due to multivalent interactions with host cell receptors [107-
109]. These ligands seek to minimize non-specific interactions between NPs and non-target 
cells reducing indiscriminate distribution of active agents at non-target sites and promoting 
localized delivery at target sites, thereby enhancing NP efficacy [110, 111].  Thus, developing 
actively targeted NPs, using specific ligands, is a promising strategy to enhance the efficacy 
of NPs. For our experiments, we utilized Coaggregation Factor A protein (CafA) as a targeting 
ligand to functionalize the BAR-NPs.  
Coaggregation Factor A Protein (CafA) 
Actinomyces oris expresses two types of heterodimeric fimbriae:  
Type 1 – Mediates the binding of the bacteria to the proline rich salivary proteins which coat 
the tooth surface.   
Type 2 – Mediates the coaggregation of streptococci and actinomyces species [135].   
The type 2 fimbriae is composed of a fimbrial shaft made of FimA subunits and tip fimbrillin 
consisting of either FimB or CafA protein. During plaque formation, CafA protein binds to the 
GalNAcβ1-3Gal motif of the receptor polysaccharides (RPS) found on oral commensal 
streptococci such as S. gordonii and S. oralis, facilitating the coaggregation of actinomyces 
and streptococci. Since CafA is the key adhesin which mediates actinomyces−streptococci 
binding [136], we anticipated that functionalization of NPs with CafA would enable us to 
actively target NPs to areas of the oral cavity harboring commensal streptococci, to gradually 
release BAR in P. gingivalis preferred niches. 
 We hypothesized that modifying the surface of BAR-encapsulated NPs with CafA, would 
enhance NP efficacy by augmenting their adhesion to commensal streptococci, facilitating 
retention for a longer duration, promoting more gradual release of BAR peptide, and resulting 
in potent inhibition of P. gingivalis adhesion to S. gordonii in a dual-species biobiofilm.  
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Figure 7: Schematic representation of type 2 fimbriae of A. oris. The type 2 fimbriae facilitates 
bacterial coaggregation and consists of a shaft comprising of FimA subunit and tip fimbrillin 
consisting of either CafA or FimB.  
Image adapted from: Reardon-Robinson, M.E., et al., Pilus hijacking by a bacterial 
coaggregation factor critical for oral biofilm development. PNAS, 2014. 111(10): p. 3835-40. 
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CHAPTER 2 
HYPOTHESIS AND SPECIFIC AIMS 
Antibiotics are commonly used as adjuncts in the treatment of periodontal diseases to prevent 
its reoccurrence [42-44]. However, the effectiveness of antibiotics in the treatment of 
periodontal diseases is limited owing to (i) biofilm-mediated resistance and (ii) reduced 
susceptibility of resistant pathogens in subgingival microflora [58]. Therefore, there is a 
compelling need to develop novel, targeted, treatment strategies beyond antibiotics for the 
prevention and treatment of periodontal diseases. 
This project builds on previous work which demonstrated that a synthetic peptide (BAR) blocks 
the P. gingivalis – S. gordonii interaction and reduces the virulence of P.gingivalis in the 
murine model of periodontitis. Furthermore, nanoparticles encapsulating BAR peptide inhibit 
the biofilm formation more potently relative to free BAR [133]. However, similar to free peptide, 
NP delivery vehicles may exhibit low retention in an open flow environment such as the oral 
cavity, necessitating administration of higher, more frequent doses. Furthermore, due to the 
time frame of peptide release (over the course of hours) from BAR-NPs, we hypothesized that 
BAR-NPs may benefit from a strategy that augments their retention in an open flow 
environment. Our vision is to develop delivery vehicles that will ultimately be incorporated into 
oral healthcare products such as oral gels which are commonly used twice daily. Therefore, 
ideally, we seek to formulate nanoparticles that will be retained in the oral cavity and release 
inhibitory concentrations of BAR peptide for a minimum of 8 to 12 hours.
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Our hypothesis is that modifying the surfaces of NPs with specific targeting moieties such as 
CafA will (i) augment the retention of the NPs in the oral cavity via multivalent interactions and 
increased avidity of contact with targeted receptor polysaccharides and (ii) prolong the release 
of BAR peptide from the NPs by facilitating a more gradual release of the encapsulant.  
 
Thus, the efficacy of the BAR- NPs can be further enhanced by modifying the surfaces of the 
BAR-NPs with a specific targeting moiety, such as CafA. Surface modification would augment 
the adhesion of the NPs to specific receptors on bacterial surfaces, facilitate their 
accumulation at target sites and promote a gradual, localized release of the BAR peptide in 
P. gingivalis preferred niches.  
 
To accomplish this, we propose three specific aims:  
Specific Aims 
1. Synthesize and characterize CafA-modified nanoparticles encapsulating BAR peptide.  
2. Evaluate the functionality of the surface modification and the release kinetics of BAR         
peptide from surface-modified NPs.  
3. Determine the efficacy of the CafA-modified NPs using biofilm inhibition assays.
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 (B) 
Figure 8: (A) Schematic representation of nanoparticles and (B) NP targeting 
strategy. Surface modification of nanoparticles with CafA protein will aid in 
directing NPs to S. gordonii for targeted delivery of BAR peptide. 
Palmitic acid Nanoparticle 
CafA protein BAR peptide 
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CHAPTER 3 
MATERIAL AND METHODS 
Peptide Synthesis 
BAR peptide consists of residues 1167 to 1193 of the SspB surface protein expressed by    
S. gordonii.  BAR peptide constitutes the following amino acid sequence:  
NH2-LEAAPKKVQDLLKKANITVKGAFQLFS-COOH 
To visualize and quantify the release of the peptide from CafA-modified NPs, 
6-carboxyfluorescien was covalently attached to the ε – amine of the lysine residue highlighted 
in red in the peptide sequence above to produce fluorescent BAR (F-BAR).  Functional studies 
of CafA-modified NPs was carried out using NPs encapsulating unlabeled BAR peptide.  Both 
labelled and unlabeled BAR peptide were synthesized by Biosynthesis, Inc. (Lewisville, TX) 
and were obtained with a greater than 94% purity. 
Growth of Bacterial Strains 
Porphyromonas gingivalis ATCC 33277 was cultured in Trypticase soy broth media (TSBY 
media) (Difco laboratories Inc., Livonia, MI, USA) supplemented with 0.5% (w/v) yeast extract, 
1 μg/ml menadione, and 5 μg/ml hemin. The growth medium was reduced for 24hr in an 
anaerobic chamber (10% CO2, 10% H2 and 80% N2). Twenty mls of reduced media was 
subsequently inoculated with 2 mls of an overnight P. gingivalis culture and incubated under 
anaerobic conditions for 48hrs at 37°C. S. gordonii DL-1, S.oralis SO34, S.mutans KPSP2 
and A actinomycetemcomitans 652 were cultured aerobically without shaking in brain-heart 
infusion (BHI) broth supplemented with 1% yeast extract for 16 hr at 37°C. 
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CafA expression and purification 
CafA synthesis was done by isolating the genomic DNA of Actinomyces oris (ATCC 43146) 
from 10 mL of an overnight culture using the Wizard Genomic DNA purification kit (Promega, 
Madison WI) as specified by manufacturer. The cafA gene was amplified by PCR using 200 
ng of genomic DNA as the template and 30 pmol each of the following primers: Forward: 5’- 
AAG GAT CCC TGA GGC CGT TCA -3’; Reverse: 5’- CCG GAA TTC TAC GAC TTG CGG 
TTG GAG-3’. PCR amplification was conducted by denaturation at 94°C for 2 min, annealing 
of primers and template at 63°C for 30 s, strand extension at 72°C for 2 min 45 s for 30 cycles, 
followed by a final extension cycle at 72oC for 5 min. 
The PCR product was subsequently electrophoresed in 1% agarose at 90 V for 40 min and 
the cafA band was excised and purified using the gel purification kit (Qiagen). The purified 
cafA DNA (1 µg) and a sample of the pGEX-6p-1 expression vector (0.5 µg) were digested 
with BamHI and EcoRI overnight at 37°C. Prior to ligation, 50 µL of the digested vector were 
dephosphorylated with 4 µL calf intestinal alkaline phosphatase (NEB) at 37°C for 30 min. 
Subsequently, 3 µL of protease K were added and incubated for 30 min at 50°C to terminate 
the reaction. The vector and cafA fragments were purified using the DNA clean and 
concentrator kit (Zymoresearch) and ligated with T4 ligase. Ligation reactions comprised 3 µL 
vector, 5 µL cafA fragment, 1 µL 10x ligase buffer and 1µL T4 ligase.  
The ligation mixture was initially transformed into E. coli Top10. Fifty µL of competent E. coli 
Top10 were incubated with 5 µL of ligation mixture on ice for 30 min, then the sample was 
heat shocked at 42°C for 45 s and placed on ice for 2 min. Two hundred µL of SOC media 
were added, the sample was incubated at 37°C for 1 hr and plated on LB agar. After overnight 
incubation at 37°C, single colonies were selected and cultured in 5 mL LB broth supplemented 
with 100 µg ampicillin. Plasmid purification was carried out using the miniprep kit (Qiagen) 
and the cafA insert was excised and confirmed by sequencing. 
40 
For CafA expression, the purified cafA plasmid was transformed into E. coli BL21 using the 
transformation protocol described above.  After selecting and confirming the appropriate 
transformant, 400 mL of LB broth was inoculated with 10 mL of an overnight culture and 
incubated to OD600 of 0.5. Protein expression was induced by the addition of 0.5 mM IPTG 
and the culture was then incubated at 18°C for 17 hr. After centrifugation at 4,250 x g, the cell 
pellet was suspended in 40 mL 50 mM Tris, 100 mM NaCl, 1 mg/mL lysozome,10 µg/mL 
Dnase I, protease inhibitor cocktail, 10 mM CHAPS, incubated overnight at 4°C, then for an 
additional 2 hr at 25°C. The cell suspension was then sonicated for 2 min on ice. 
CafA purification was carried out with the Pierce GST Spin Purification Kit (Thermo Fisher). 
Seventeen mL of crude cell lysate were bound to the GST column for 2 hr at room temperature 
and the column was then centrifuged to remove unbound protein according to the 
specifications of the manufacturer. After washing the column with loading buffer, the GST tag 
was cleaved by the addition of 50 µL precision protease (GE Health) and overnight incubation 
at 4°C. Released CafA was then collected by centrifugation. The sample was then sequentially 
dialyzed against 30 mM, 20 mM, and 10 mM Tris for 2 hr each. CafA purity was determined 
by PAGE gels and protein concentration was determined using the BCA assay (Pierce). 
Conjugation of CafA protein with Palmitic acid (CafA-Palmitate Synthesis) 
CafA-palmitate was synthesized as previously described [137-139]. Briefly, 2 mg of purified 
CafA was dissolved in 1.2 mL of 2% (w/v) sodium deoxycholate (NaDC) in phosphate-buffered 
saline (137 mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4, 10 mM Na2HPO4; PBS) and warmed to 
37°C. Next, a solution with 14-fold molar excess of the palmitic acid-N-hydroxysuccinimide 
ester (NHS- palmitic acid; Sigma-Aldrich, St Louis, MO, USA) was prepared by dissolving 
NHS–palmitic acid in 2% (w/v) NaDC at 0.125 mg/mL. The solution was sonicated until well 
mixed in an ultrasonic bath and 800 uL of this solution was added dropwise to the reaction 
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vial containing CafA and reacted overnight at 37°C. To remove excess fatty acid and 
hydrolyzed ester, reactants were dialyzed against 1.2 L of PBS with 0.15% deoxycholate, 
using a 3,500 molecular weight cut-off dialysis tube. After overnight dialysis at 37°C, CafA-
palmitate was stored at 4°C until use. 
 
Synthesis of CafA-modified nanoparticles 
 
Nanoparticles were synthesized using poly(lactic-co-glycolic acid) (PLGA) carboxyl-
terminated polymer (0.55–0.75 dL/g inherent viscosity; LACTEL®). To formulate CafA-
modified nanoparticles, a previously described oil-in-water (o/w) single emulsion technique 
was used [140, 141].  Briefly, 100 mg PLGA was dissolved in 2 mL dichloromethane (DCM) 
by overnight incubation at 25°C. The next day, 2 mL of 5% (w/v) polyvinyl alcohol (PVA) was 
added to 2mL CafA-palmitate solution. This solution was vortexed and 2 mL of PLGA/DCM 
solution was added to it in a dropwise manner. The resulting solution was ultrasonicated and 
excess DCM was evaporated by adding the solution to 50 mL of 0.3% (w/v) PVA and mixing 
using a magnetic stir bar for 3 hr. After evaporation, the NP solution was centrifuged at 13,000 
rpm (20,442 x g) at 4°C for 10 min. The supernatant was discarded, and the NPs were washed 
twice with deionized water (diH2O) followed by centrifugation at 13,000 rpm (20,442 x g) at 
4°C for 10 min. After washing, CafA-modified NPs were suspended in 5 mL of diH2O, freeze 
dried at -80°C and lyophilized. 
 
Synthesis of CafA-modified NPs encapsulating C6/F-BAR/BAR 
 
For our experiments, three different types of CafA-modified NPs were synthesized. CafA-
modified NPs encapsulating the fluorescent dye, Coumarin6 (C6), were synthesized to assess 
the binding functionality of CafA surface modification. CafA-modified NPs encapsulating 
fluorescent BAR (F-BAR) were synthesized to determine the loading and controlled release 
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characteristics of the NPs, and CafA-modified NPs encapsulating unlabeled BAR were 
synthesized to determine the efficacy of NP-mediated inhibition of P. gingivalis adherence to 
streptococci using a two-species biofilm model.  
CafA-modified NPs encapsulating C6 were synthesized using a previously described w/o/w 
double emulsion solvent evaporation technique [138, 139]. Briefly, C6 was dissolved overnight 
in 200 μl DCM at a concentration of 15 μg/mg PLGA. In parallel, 100 mg of PLGA crystals 
were dissolved in 2 ml of DCM by overnight incubation at 25°C.  The following day, the C6 
DCM solution was first emulsified in the PLGA/DCM solution by vortexing followed by 
ultrasonication to achieve a homogenous suspension. Next, the homogenous suspension was 
added dropwise to a mixture of 2ml of 5% (w/v) polyvinyl alcohol (PVA) and 2ml CafA-
palmitate while vortexing followed by ultrasonication. Excess DCM was evaporated and NPs 
were collected as described above. CafA-modified NPs encapsulating F-BAR/BAR were 
synthesized using a similar approach.  All synthetic reactions were protected from exposure 
to light. For the synthesis of CafA-modified NPs encapsulating either F-BAR or unlabeled 
BAR, the peptide was dissolved in 200 μl Tris EDTA buffer (VWR; 100 mM Tris HCl,10 




Figure 9: (A) Schematic representation of synthesis of CafA-modified NPs encapsulating 
BAR peptide using double emulsion solvent evaporation technique. (B) Collection of NPs after 
solvent evaporation, centrifugation and washing.  
Bottom image adapted from McCall, R.L., Sirianni, R.W. PLGA Nanoparticles Formed by Single or 
Double-emulsion with Vitamin E-TPGS. J. Vis. Exp. (82), e51015.      
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NP Characterization: NP morphology and size 
Unhydrated NP morphology, diameter, and size distribution were determined using scanning 
electron microscopy (SEM, XL-30 ESEM-FEG SEM, FEI Company, USA). Lyophilized NPs 
were mounted on carbon tape and sputter coated with a thin layer of gold/palladium. Average 
diameters of 500 particles were determined from SEM images (n=3) using image analysis 
software (ImageJ, National Institutes of Health, version 1.5a, ImageJ.nih.gov).  
Quantification of Surface Density of CafA 
CafA-modified NPs were synthesized using varying input concentrations of CafA protein 
(5 to 80 ug/mg polymer). For each input condition, the resulting concentration of CafA 
conjugated to the NP surface was measured using the microBCA assay (Pierce). CafA-
modified NPs (1 mg) were suspended in 1% dimethyl sulfoxide (DMSO) in PBS. Aliquots (100 
uL) of the NP samples were analyzed in triplicate in a microtiter plate and NP-associated 
absorbance was measured by spectrophotometry at a wavelength of 562 nm. The 
concentration of CafA was determined by comparing absorbance values to a known standard 
curve of CafA and subtracting the background absorbance values of unmodified NPs (control 
group).  
Loading and release kinetics of BAR peptide from unmodified and CafA-modified NPs 
Nanoparticles modified with an intermediate density of CafA (20 ug/mg polymer) were 
selected for subsequent characterization and functionality studies. To determine BAR peptide 
loading, approximately 2 mg CafA-modified NPs encapsulating F-BAR were dissolved in 1 mL 
DMSO. Aliquots (100 uL) of the NP samples were analyzed in triplicate in a microtiter plate 
and the amount of F-BAR in the dissolved solution was determined by measuring fluorescence 
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(488/518 nm excitation/emission) and quantified by comparing these values to a known 
standard curve of F-BAR.  
To analyze the release kinetics of F-BAR, aliquots of CafA-modified and unmodified NPs 
encapsulating F-BAR were incubated in microcentrifuge tubes containing 1 mL PBS (pH 7.4) 
at 37ºC with gentle horizontal agitation. At fixed time points (1, 2, 4, 8, and 24 hr) after the 
initial suspension, the samples were centrifuged at 18,900 x g and the supernatant was 
collected. The pelleted NPs were then suspended in fresh PBS and incubated until the next 
time point. The amount of F-BAR in the supernatant was determined by measuring 
fluorescence (488/518nm excitation/emission) and quantified by comparing these values to a 
known standard curve of F-BAR. 
Determination of functionality of surface modification 
The functionality of surface modification and preservation of the function of CafA protein 
during NP synthesis was analyzed using two approaches.   
To determine the duration of retention of CafA-modified C6 NPs on S. gordonii DL-1 cells, 
S. gordonii was cultured as previously described and bacterial cells were harvested by 
centrifuging 10 mL of culture at 3700 x g for 5 min. The supernatant was discarded and the 
pelleted cells were suspended in 1 mL of 1X PBS. The O.D. at 600 nm of the cell suspension 
was adjusted to 0.2 and 100 µL of the S. gordonii cell suspension was added to each well of 
a 96-well microtiter plate and incubated overnight at 4°C. After removing unbound cells, the 
wells were blocked for non-specific binding with 300 µL of 0.3% bovine serum albumin (BSA) 
for 1 hr. Thereafter, the microtiter plate was washed three times with 1X PBS containing 0.05% 
Tween (PBST). Immobilized S. gordonii cells were then incubated with 100 µL of CafA-
modified C6 NPs (0.25 mg/mL), avidin-modified C6 NPs (0.25 mg/mL) or PBST in the absence 
of NPs in triplicate for 1 hr on a rocker platform. After washing three times with PBST, the cell-
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associated fluorescence was measured using Synergy HT reader (BioTek, Winooski, VT, 
USA) (485/520 nm excitation/emission). After subtracting the control fluorescence (S. gordonii 
in PBST), this initial reading (at t = zero) was defined as 100% binding. After obtaining the 
initial reading, 100 µL of PBST was added to each well and at fixed time points (1, 2, 4 and 8 
hr), the PBST was removed and the cell-associated fluorescence that remained was 
measured.  Subsequently, an additional aliquot of fresh PBST was added per well and 
incubated until the next time point was reached.  
For determining the specificity of CafA adhesion, the adherence of CafA-modified C6 NPs to          
S. gordonii DL-1, S. oralis SO34, P. gingivalis ATCC 33277, A. actinomycetemcomitans 652 
or S. mutans KPSP2 cells was measured. CafA binds to receptor polysaccharides (RPS) 
found only on commensal oral streptococci such as S. gordonii and S. oralis. It does not bind 
to bacteria that are RPS- negative and therefore, P. gingivalis ATCC 33277, A. 
actinomycetemcomitans 652 and S. mutans KPSP2 were selected as negative bacterial 
controls. Each of the organisms was cultured and harvested as described previously, and the 
final O.D. at 600 nm for each cell suspension was adjusted to 0.2. The bacterial cells were 
immobilized on a 96-well microtiter plate as described above and after overnight incubation, 
wells were blocked for non-specific binding with 300 µL of 3% bovine serum albumin (BSA) 
for 1 hr. The plate was washed three times with PBST and immobilized bacterial cells were 
incubated with 100 µL of CafA-modified C6 NPs (0.25 mg/mL) or with PBST in triplicate for 1 
hr on a rocker platform. The microtiter plate was again washed three times with PBST and 
cell-associated fluorescence was measured (485/520 nm excitation/emission). To determine 
the final cell associated fluorescence, the reading obtained from bacteria incubated in PBST 
alone (background) was subtracted from that of bacteria incubated with CafA-modified C6 
NPs. Data was analyzed using an unpaired t-test.
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Figure 10: Schematic of duration of retention assay. S. gordonii cells were immobilized on a 
microtiter plate and incubated with CafA C6-NPs. At fixed time points, the supernatant 
containing the unbound NPs was removed and the cell associated fluorescence was 
measured.  Thereafter, fresh buffer was added to the wells, until the next time point was 
reached. Avidin-modified C6 NPs were used as controls. To measure specificity of adhesion, 
adherence of CafA-modified NPs to S. mutans KPSP2, S. oralis SO34, P. gingivalis ATCC 
33277 or  A. actinomycetemcomitans 652 cells was compared to the level of adherence to S. 
gordonii DL-1 cells. 
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CafA-modified NP-mediated inhibition of P. gingivalis adherence to streptococci 
S. gordonii DL-1 was cultured as previously described and bacterial cells were harvested by 
centrifuging 10 mL of culture at 3700 x g for 5 min. The supernatant was discarded, and the 
pelleted cells were suspended in 1 mL of 1X PBS in a microcentrifuge tube. The cells were 
labelled with 20 µL of 10 mM hexidium iodide (Thermo Fisher Scientific) for 15 min on a rocker 
platform at room temperature. The microcentrifuge tube was covered with foil, centrifuged at 
3700 x g for 5 min, and the pelleted cells were suspended in 1 mL of 1X PBS. The O.D. at 
600 nm was measured as previously described and adjusted to 0.8. One mL of the resulting 
cell suspension was added to each well of a 12-well microtiter plate containing a glass 
coverslip. The cells were incubated overnight under anaerobic conditions on a rocker platform 
and protected from light. 
On the following day, the wells were washed to remove unbound S. gordonii cells. The 
immobilized S. gordonii cells were incubated with CafA-modified BAR NPs (treatment) or 
CafA-modified blank NPs (control) at a concentration of 240 µg/mL for different durations on 
a rocker platform. Due to the 50% inhibitory concentration (IC50) of free BAR peptide 
equivalent to 1.3 µM or ~4 µg, and NP loading results, we calculated that 240 µg CafA-
modified BAR NPs would encapsulate an equivalent amount of BAR. After the first hour of 
binding (t = 0) and at each subsequent time point  (t =  2, 4, 8, 12 hr) the supernatant containing 
the unbound NPs and released BAR was removed and P. gingivalis was added in triplicate to 
the control and treatment plates as described below.   
P. gingivalis ATCC 33277 was cultured and harvested as previously described. P. gingivalis 
was labelled with 15 µL of 5-(6) carboxyfluorescien-succinylester (4 mg/mL) for 30 min, 
centrifuged at 3700 x g for 2 min and the pelleted cells were suspended in 1 mL of 1X PBS. 
The O.D. at 600 nm was measured and adjusted to 0.4. At each time point, 1 mL of labelled 
P. gingivalis cell suspension (O.D. 0.4) was added to the treatment and control plates in 
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triplicate. The plates were incubated at 37 °C for 24 hr under anaerobic conditions. The 
subsequent day the supernatant was removed, the wells were washed with 1X PBS to remove 
the unbound bacterial cells. The adherent cells were fixed with 4% (w/v) paraformaldehyde. 
The coverslips were mounted on a glass slide using Prolong gold anti-fade reagent and fixed 
with clear nail polish. The prepared slides were stored at 4°C.  
Confocal Microscopy and Imaging 
The dual-species biofilms were visualized using a LEICA SP8 confocal microscope (Lieca 
Microsystems Inc., Buffalo Grove, IL) under 60 X magnification. Three dimensional z-stack 
biofilm images were obtained using a z-step size of 0.7 µm. Images were analyzed using 
Volocity software (version 6.3; Perkin Elmer, Waltham, MA, USA) to quantify the bacterial 
populations by quantifying fluorescence (S. gordonii – red, P. gingivalis – green).  Adherence 
of P. gingivalis to streptococci was determined by measuring the green to red fluorescence 
ratio (GR). Inhibition at each time point was analyzed in triplicate (treatment and control plates) 
and three independent frames were obtained for each well. The percentage of P. gingivalis 
inhibition was calculated using the formula: (1- GR treatment /GR control) * 100. The mean 
and S.D. of inhibition at each time point was calculated and the data was analyzed using a 
paired t-test.  
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           Visualize 
biofilms using confocal 
microscope 
Measure GR ratio using Volocity software 
      % adherence inhibition P. g. = 1-GR(S)/GR(C)×100 
Figure 11: Schematic representation of inhibition assay using dual-species biofilm. The 
efficacy of the CafA-modified NPs was evaluated by performing functional inhibition assays 






NP Characterization: NP morphology and size 
 
The morphology of CafA-modified BAR NPs, relative to unmodified BAR NPs, is shown in 
Figure 12. CafA-modified BAR NPs demonstrated a spherical morphology and were smaller 
relative to unmodified BAR NPs. The average unhydrated diameters of CafA-modified BAR 
NPs and unmodified BAR NPs measured from SEM images were 89.7 ± 26.3 nm and 165.8 







*Figure 12: SEM images of (A) CafA-modified BAR-encapsulated NPs and (B) Unmodified
BAR-encapsulated NPs PLGA NPs. Images are representative of a minimum of 3 
independent samples, with n > 500 NPs assessed in total. Scale bar represents 1 µm. 
*This data was collected by Mohamed Y. Mahmoudd
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Quantification of ligand surface density 
The concentration of CafA conjugated to the surface of the NP was measured using the 
microBCA assay. The total protein content ranged from 3 to 36 µg CafA/mg polymer and 
varied directly with the input concentration of CafA (5 to 80 µg CafA/mg polymer) used during 
synthesis. The conjugation efficiency ranged from 45 to 79%, with higher conjugation
efficiency observed at lower concentrations (Figure 13, Table 2). Although saturation was not 
achieved under these conditions, the results suggest that an increased surface density may be 
attained with higher CafA input.  
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**Figure 13:  Quantification of surface density of ligands. The total amount of CafA conjugated 
to the NP surface was determined using the microBCA assay. The amount of CafA conjugated 
to the NP surface varied directly with the input concentration of CafA during synthesis. Data 
represent mean NP associated CafA ± S.D, n = 3. 
Table 2: Input and output concentration of CafA 
**Data collected together with Mohamed Y. Mahmoudd 
Input 
Concentration 
(µg CafA/ mg NP) 
Output 
Concentration 
(µg CafA/ mg NP) 
Conjugation 
Efficiency (%) 
5 2.9 ± 0.1 58 
10 7.9 ± 1.9 79 
20 14.4 ± 2.6 72 
40 25.4 ± 2.2 64 
80 36.3 ± 3.5 45 
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Loading and release kinetics of BAR peptide from unmodified and CafA-modified NPs 
Nanoparticles modified with an intermediate density of CafA (20 ug/mg polymer) were 
selected for subsequent characterization and functionality studies, as they represent a 
practical minimum modification density that in preliminary studies (and results here) provided 
a therapeutically-relevant concentration of BAR release. To determine the loading of BAR 
peptide in unmodified and CafA-modified NPs, the amount of F-BAR from dissolved NPs was 
determined by measuring fluorescence (488/518 nm excitation/emission) and quantified by 
comparing these values to an F-BAR standard curve. Loading experiments showed that 
unmodified and CafA-modified NPs encapsulated 16.95 ± 0.8 and 15.73 ± 1.9 µg of BAR per 
mg of NP respectively, corresponding to loading efficiencies of 39% and 37% (Table 3), 
suggesting that surface modification at this density had minimal effect on BAR loading.  
To measure BAR release, sample eluates were taken 1, 2, 4, 8, and 24 hr after incubation in 
PBS. The overall release trends showed that CafA-modified NPs demonstrated slower 
release of BAR, relative to unmodified NPs; however, inhibitory concentrations of BAR peptide 
(2 to 4 µg/mg NP) were released from CafA-modified NPs at each of the measured time points 
up to 8 hr. For unmodified NPs, more rapid release profiles were observed, with greater than 
50% of BAR peptide released within 1 hr and a plateau in release after. After 2, 4, 8 and 24 
hr, less than 1 µg of peptide/mg NP was released from the unmodified NPs (Figure 14), 
demonstrating inadequate, non-inhibitory levels of release. In comparison, CafA-modified NPs 
released 23% of BAR during the first hour, and inhibitory concentrations (3.1, 2.7, 2.9, and 
3.3 µg/mg) of BAR peptide after 2, 4, 8, and 24 hr. Cumulatively, after 24 hr, BAR peptide 
(15.5 µg/mg) was completely released from CafA-modified BAR NPs, whereas 61% of the 
encapsulated BAR (10.3 µg/mg) was released from unmodified BAR-encapsulated NPs. 
Thus, after 24 hr, the total quantity of BAR released from CafA-modified NPs was significantly 
higher than the amount of BAR released from unmodified NPs.  
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**Table 3: Encapsulation efficiency of CafA-modified and unmodified NPs. 





Unmodified NPs 43 16.95 ± 0.8 39.4 




**Figure 14: Release kinetics of BAR peptide from unmodified and CafA-modified NPs 
Cumulative release of BAR as (A) function of mass (µg BAR per mg NP) and (B) percent of 
total BAR loaded over 24 hr. Asterisks denote a statistically significant difference between two 
groups (* p < 0.01, ** p < 0.001, *** p < 0.0001, **** p < 0.00001).  




Determination of functionality of surface modification 
Duration of retention of CafA-modified C6 NPs 
CafA-modified C6 NPs were incubated with immobilized S. gordonii cells for 1 hr, after which 
unbound NPs were washed and cell-associated fluorescence was measured to determine the 
amount of NPs that initially bound to S. gordonii (t = 0). As shown in Figure 15A, after the first 
hour of binding (t = 0), CafA-modified NPs bound to S. gordonii at a 2.3-fold higher 
concentration (5.7 µg/mL), relative to non-specific avidin-modified NPs (2.5 µg/mL). The most 
significant dissociation of CafA-modified NPs from S. gordonii was observed within 1 hr of 
assessing initial binding (t = 1), after which NP dissociation stabilized for both CafA-modified 
and avidin-modified NPs. After 8 hr, 65% (3.7 µg/mL) of CafA-modified and 56% of avidin-
modified NPs (1.4 µg/mL) remained associated with S. gordonii, resulting in a 2.5-fold higher 
concentration of CafA-modified NPs bound to S. gordonii  (Figure 15B). These results indicate 
that the ratio of CafA-modified to avidin-modified NPs bound to S. gordonii was maintained 
after the first wash and suggest that CafA modification enhances NP retention by increasing 
the concentration of NPs that initially bind to S. gordonii. After 8 hr, similar rates of subsequent 




**Figure 15: Duration of retention of CafA-modified C6 NPs. (A) After one hour of initial 
binding (t=0),  a 2.3-fold higher concentration of CafA-modified C6 NPs (5.7 ug/mL) bound to 
S. g. relative to avidin-modified C6 NPs (2.5 µg/mL) and this difference in concentration was 
maintained for up to 8 hr. (B) 65% of CafA-modified C6 NPs remain bound to S. g. after 8 hr. 
(C) Concentration of CafA-modified NPs bound to S. g. normalized against Avidin-modified 
NPs. Asterisks denote a statistically significant difference between two groups (* p < 0.01, ** 
p < 0.001, *** p < 0.0001, **** p < 0.00001).  




































Specificity of adhesion of CafA-modified C6 NPs 
While the overall binding of CafA-modified NPs to S. gordonii is important, we sought to 
assess the differences in CafA-modified NP binding across several bacteria to determine the 
specificity of NP adhesion. The adherence of CafA-modified NPs to S. gordonii DL-1 was 
measured relative to S. oralis SO34, S. mutans KPSP2, P. gingivalis ATCC 33277 and A. 
actinomycetemcomitans 652 cells. For commensal oral streptococci, S. gordonii DL-1 and S. 
oralis SO34, that express the receptor polysaccharides (RPS), there was no statistical 
significance in the concentration of bound CafA-modified NPs between groups. For bacterial 
groups that were RPS-negative, CafA-modified NPs bound to S. gordonii DL-1 at a 1.8-fold 
higher concentration relative to S. mutans KPSP2 and 2.6-fold higher concentration relative 
to P. gingivalis ATCC 33277 and A. actinomycetemcomitans 652. The concentration of CafA-
modified NPs bound to S. gordonii DL-1 relative to S. mutans KPSP2, P. gingivalis ATCC 
33277 and A. actinomycetemcomitans 652 was found to be statistically significant (P ≤ 0.05). 
Among non-commensal streptococci, the concentration of CafA-modified NPs bound to S. 
mutans KPSP2 relative to P. gingivalis ATCC 33277 and A. actinomycetemcomitans 652 was 
found to be statistically significant (P ≤ 0.05). 
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Figure 16: Specificity of CafA-modified C6 NP adhesion. CafA binds the receptor 
polysaccharides (RPS) found only on commensal oral streptococci such as S. gordonii and 
S. oralis. It does not bind to bacteria lacking the receptor and therefore, CafA-modified NPs 
bound to S. gordonii DL-1 (S. g.) and S. oralis SO34 (S. o.) at a higher concentration than S. 
mutans KPSP2 (S. m.), P. gingivalis ATCC 33277(P. g.), and A.actinomycetemcomitans 652 
(A. a.), demonstrating specificity of adherence. Asterisks denote a statistically significant 
difference between two groups (* p < 0.01, ** p < 0.001, *** p < 0.0001, **** p < 0.00001). 
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CafA-modified NP-mediated Inhibition of P. gingivalis adherence to streptococci 
 
Functional inhibition assays were performed to determine the impact of CafA-modified BAR 
NPs on the inhibition of P. gingivalis adhesion to S. gordonii. Immobilized S. gordonii were 
incubated with CafA-modified BAR NPs (treatment group) or CafA-modified blank NPs 
(control control) for 1 hr. After the first hour of binding (t = 0) and at each subsequent time 
point (t = 2, 4, 8, 12 hr) the supernatant containing the unbound NPs and released BAR was 
removed and P. gingivalis was added to the control and treatment plates The plates were 
incubated for 24 hr and the formed biofilms were visualized using confocal microscopy. 
Representative images of treatment and control biofilms are shown in Figure 17. At each time 
point (t = 0, 2, 4, 8 and 12 hr), P. gingivalis adherence to S. gordonii was significantly reduced 
in the presence of CafA-modified BAR NPs, relative to control CafA-modified blank NPs 
(Table 4). After initial administration for one hour (t = 0), P. gingivalis adherence was inhibited 
by 87.9 ± 4.1% and maintained more than 80% inhibition after 2 and 4 hr, relative to control 
CafA-modified blank NPs. After 8 and 12 hr, time frames relevant to oral administration 
regimens, P. gingivalis binding to S. gordonii was inhibited by 66.3 ± 4.1% and 40.6 ± 9.3%, 
demonstrating the potential of CafA-modified BAR NPs to significantly inhibit P. gingivalis 









Figure 17(A-E): Functional inhibition assay demonstrating inhibition of P. gingivalis 
adherence to S. gordonii. CafA-modified BAR NPs inhibited P. gingivalis adherence for more 
than 8 hr relative to CafA-modified blank NPs (control). Biofilms were visualized using confocal 
microscopy and the ratio of green (P. g) to red (S. g.) fluorescence in z-stack images was 






Table 4: Percent inhibition of P. gingivalis adherence to S. gordonii at various time points. 
Time Point Inhibition of P.g. Adherence (%) 
t = 0 hr 87.9 ± 4.1 
t = 2 hr 85.5 ± 2.6 
t = 4 hr 81.4 ± 9.7 
t = 8 hr 66.3 ± 4.1 




The adherence of P. gingivalis to S. gordonii is a crucial, initial event which facilitates the 
colonization of P. gingivalis in the oral cavity. The binding of P. gingivalis to S. gordonii is 
driven by a protein−protein interaction between Mfa1, the structural subunit of the minor 
fimbriae of P. gingivalis, and discrete domains of the streptococcal cell surface protein, SspB, 
of the antigen I/II family [125, 127, 142, 143]. These early interactions provide ideal targets for 
therapeutic interventions to limit the supragingival colonization of P. gingivalis in the oral 
cavity. Previous studies have shown that a synthetic peptide designated BAR potently inhibits 
P. gingivalis/S. gordonii adherence and reduces the virulence of P. gingivalis in a murine 
model of periodontitis [67, 128, 129]. However, owing to the constant flow of saliva in the oral 
cavity, free peptide is only transiently retained. Moreover, a higher concentration of free 
peptide is needed to disrupt pre-established P. gingivalis biofilms.  
To overcome this challenge, we developed polymeric nanoparticles that encapsulate BAR. 
BAR-encapsulated NPs (IC50 = 0.7 µM) were found to be more efficacious relative to free 
peptide (IC50 = 1.3 µM) and inhibited pre-established biofilms potently. However, similar to 
free peptide, BAR-encapsulated NPs also lack a mechanism by which to prolong retention in 
the oral cavity. Since BAR-encapsulated NPs release BAR peptide over the course of hours, 
they may benefit from a strategy to augment their retention in the oral cavity [133]. Given this, 
the goal of this study was to formulate NPs with improved binding to the GalNAcβ1-3Gal motif 
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of the receptor polysaccharides (RPS) expressed by commensal oral streptococci. In parallel 
we sought to prolong the release of inhibitory concentrations of BAR peptide for 8 to 12 hr, for 
future application in oral hygiene products, such as oral gels, that are traditionally 
administered twice daily. 
CafA is the tip fimbrillin of type 2 fimbriae of A. oris, and during plaque development, it 
mediates the coaggregation of A. oris with commensal oral streptococci. CafA binds to the 
GalNAcβ1-3Gal motif of the RPS found on commensal oral streptococci such as S. gordonii 
and S. oralis that promote P. gingivalis adherence. We hypothesized that functionalization of 
BAR-encapsulated NPs with CafA would promote the adherence of BAR-encapsulated NPs 
to oral commensal streptococci such as S. gordonii, indicating future potential in targeting to 
S. gordonii harboring niches of the oral cavity.  Since the S. gordonii/P. gingivalis interaction 
promotes supragingival P. gingivalis colonization, accumulation of BAR-encapsulated NPs 
and the localized, prolonged release of BAR from this niche may potently inhibit S. gordonii/P. 
gingivalis biofilm formation and reduce P. gingivalis colonization of the oral cavity. 
Surface modification of the NPs with ligands such as CafA can be accomplished in two ways; 
(i) by chemical conjugation or physical adsorption of the ligands on the NP surface after NP 
formation, or  (ii) by linking the ligands to components of the NP (eg: polymer) before formation 
[144]. Previous studies have shown that the lack of functional groups on the aliphatic polyester 
backbone of PLGA makes coupling ligands on the surfaces of the nanoparticles particularly 
challenging. While adsorption of ligands on the surfaces of the NPs is an effective approach 
for surface modification, there are drawbacks associated with this approach including limited 
density of surface ligands and decreased targeting effects over time due to desorption of 
ligands and NP degradation [137]. It has been previously shown that coupling ligands with a 
lipid (eg: palmitic acid) to form an amphiphilic molecule prior to NP synthesis enhances the 
density of ligands incorporated into the PLGA matrix and helps to achvieve a stable protein 
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coat on NP surfaces [137, 145, 146]. To facilitate a sustained presentation of ligands, we 
conjugated CafA to palmitic acid prior to its addition during NP synthesis.  
Following synthesis, we selected NPs with an intermediate density of surface ligands (20 
µg/mg polymer) for further characterization and functional studies. Although in general, higher 
ligand density increases binding avidity via multivalent interactions, several studies have 
reported that NPs with intermediate ligand density exhibit higher binding relative to higher 
ligand densities [116-118]. Several explanations have been offered for this effect including 
steric interference; improper ligand orientation which may impede ligand function; or ligand 
overcrowding, leading to competition between ligands for the same receptor [116-118]. 
Additionally, these reports have suggested that increasing the ligand density beyond a certain 
threshold does not improve binding efficiency [147, 148]. While NPs were formulated with an 
intermediate CafA concentration, due to the feasibility of using a practical amount of peptide 
and the satisfactory release properties, these results demonstrate the effectiveness of the 
formulated NPs in functionality and efficacy. Future studies may focus on improving the 
efficacy of CafA-modified NPs by tuning ligand surface density to optimize binding efficiency 
without impeding BAR release kinetics. 
 
While both formulations exhibited high peptide loading, it is well known that polymeric NPs 
that encapsulate hydrophilic agents demonstrate high burst release due to the entrapment of 
the encapsulant in the form of small clusters on the surface or within the polymer matrix just 
below the surface of the particles during synthesis [149]. Studies have shown that surface 
modification using amphipathic molecules slows the release of the encapsulant from the 
polymeric NPs [102, 137, 149-151] due to the increased hydrophobic stabilization and uniform 
dispersion of the encapsulant in the polymer matrix [152]. Our results were consistent with 
these findings in that unmodified BAR NPs demonstrated more rapid release corresponding 
to a burst (< 50% peptide) within one hour of delivery. We attribute these findings to the 
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release of BAR that is adsorbed at, or just underneath the surface of the polymer matrix. After 
the first hour, minimal additional peptide was released from unmodified NPs. In comparison, 
CafA-modified NPs demonstrated a more gradual release of BAR peptide over 24 hr, likely 
because to the increased hydrophobic stabilization and uniform dispersion of the peptide 
within the matrix due to the presence of the Caf-palmitate conjugates on the NP surface. 
Cumulatively over 24 hr, while 61% of the BAR peptide was released from unmodified NPs, 
Caf-modified NPs exhibited a near complete release of the BAR peptide. This improved 
release was likely due to surface modification with hydrophilic ligands, which facilitated the 
drawing out of a higher amount of BAR peptide from CafA-modified NPs, promoting a 
complete release of the peptide payload.   
In addition to high loading and favorable release kinetics, another desirable characteristic is 
NP retention at target sites for a prolonged duration. Given the site-specific nature of 
periodontal disease, local application of therapeutic agents has been found to have better 
patient acceptance, reduced side-effects and improved clinical outcomes. Although 
therapeutic agents applied directly to periodontal pockets are effective, they too get drained 
by the gingival crevicular fluid and saliva flow. Therefore, improving the binding characteristics 
of delivery vehicles can increase residence time at target sites and enhance NP efficacy. Here 
we targeted CafA-modified NPs to RPS-expressing bacteria such as S. gordonii, which 
promote P. gingivalis colonization. Our results suggest that CafA-modified NPs demonstrate 
high binding efficiency and specificity to RPS-expressing commensal bacteria relative to other 
bacteria including S. mutans, P. gingivalis and A.actinomycetemcomitans. Moreover, CafA-
modified NPs remained bound to S. gordonii cell surfaces for a prolonged duration (over 8 hr). 
Functionally, in a dual-species biofilm, CafA-modified NPs inhibit P. gingivalis adherence to 
S. gordonii potently for up to 8 hr.  While these results seem promising, future experiments 
will seek to develop NPs that can be retained at target sites for longer durations (12-24 hr). 
68 
Overall our study suggests that surface modification of NPs with specific biological ligands 
such as CafA can facilitate NP targeting and adherence to specific receptors on the surfaces 
of S. gordonii cells for a prolonged duration. Moreover, CafA-modified NPs release inhibitory 
concentrations of the BAR peptide and potently inhibit P. gingivalis adherence to S. gordonii 
for a duration of time relevant to delivery in the oral cavity. CafA-modified NPs represent an 
efficacious vehicle for targeting BAR peptide to P. gingivalis preferred niches.  
Future experiments will focus on optimizing the surface density of CafA and evaluating the 
functionality of these NPs. We anticipate that optimizing the surface density of CafA further 
will also enhance the retention, drug loading and release kinetics of modified NPs for 12 to 24 
hr. In the long term, we hope to apply this work to incorporate CafA-modified NPs into oral gel 
formulations and test their effectiveness in clinical trials.
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